COCRYSTAL PHARMA INC (COCP) Fundamental Analysis & Valuation

NASDAQ:COCP • US19188J4094

1.03 USD
-0.03 (-2.83%)
Last: Mar 4, 2026, 04:15 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This COCP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

COCP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. COCP has a great financial health rating, but its profitability evaluates not so good. COCP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. COCP Profitability Analysis

1.1 Basic Checks

  • COCP had negative earnings in the past year.
  • In the past year COCP has reported a negative cash flow from operations.
  • In the past 5 years COCP always reported negative net income.
  • COCP had a negative operating cash flow in each of the past 5 years.
COCP Yearly Net Income VS EBIT VS OCF VS FCFCOCP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • COCP has a Return On Assets of -92.58%. This is in the lower half of the industry: COCP underperforms 75.65% of its industry peers.
  • COCP's Return On Equity of -126.11% is on the low side compared to the rest of the industry. COCP is outperformed by 65.28% of its industry peers.
Industry RankSector Rank
ROA -92.58%
ROE -126.11%
ROIC N/A
ROA(3y)-95.52%
ROA(5y)-64.44%
ROE(3y)-118.44%
ROE(5y)-78.4%
ROIC(3y)N/A
ROIC(5y)N/A
COCP Yearly ROA, ROE, ROICCOCP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for COCP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COCP Yearly Profit, Operating, Gross MarginsCOCP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. COCP Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for COCP remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for COCP has been increased compared to 5 years ago.
  • COCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COCP Yearly Shares OutstandingCOCP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
COCP Yearly Total Debt VS Total AssetsCOCP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • COCP has an Altman-Z score of -44.64. This is a bad value and indicates that COCP is not financially healthy and even has some risk of bankruptcy.
  • COCP has a worse Altman-Z score (-44.64) than 90.67% of its industry peers.
  • COCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -44.64
ROIC/WACCN/A
WACCN/A
COCP Yearly LT Debt VS Equity VS FCFCOCP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 5.78 indicates that COCP has no problem at all paying its short term obligations.
  • COCP has a Current ratio of 5.78. This is in the better half of the industry: COCP outperforms 66.84% of its industry peers.
  • COCP has a Quick Ratio of 5.78. This indicates that COCP is financially healthy and has no problem in meeting its short term obligations.
  • COCP's Quick ratio of 5.78 is fine compared to the rest of the industry. COCP outperforms 67.88% of its industry peers.
Industry RankSector Rank
Current Ratio 5.78
Quick Ratio 5.78
COCP Yearly Current Assets VS Current LiabilitesCOCP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. COCP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 49.19% over the past year.
EPS 1Y (TTM)49.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • COCP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.61% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y53.13%
EPS Next 2Y23.86%
EPS Next 3Y12.61%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
COCP Yearly Revenue VS EstimatesCOCP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2019 2020 2M 4M 6M
COCP Yearly EPS VS EstimatesCOCP Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. COCP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for COCP. In the last year negative earnings were reported.
  • Also next year COCP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COCP Price Earnings VS Forward Price EarningsCOCP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COCP Per share dataCOCP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • COCP's earnings are expected to grow with 12.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.86%
EPS Next 3Y12.61%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. COCP Dividend Analysis

5.1 Amount

  • No dividends for COCP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

COCP Fundamentals: All Metrics, Ratios and Statistics

COCRYSTAL PHARMA INC

NASDAQ:COCP (3/4/2026, 4:15:31 PM)

1.03

-0.03 (-2.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners4.82%
Inst Owner Change15.89%
Ins Owners15.13%
Ins Owner Change1.16%
Market Cap14.19M
Revenue(TTM)N/A
Net Income(TTM)-9.67M
Analysts82.5
Price Target6.12 (494.17%)
Short Float %2.54%
Short Ratio3.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.97%
Min EPS beat(2)11.3%
Max EPS beat(2)34.64%
EPS beat(4)4
Avg EPS beat(4)35.52%
Min EPS beat(4)11.3%
Max EPS beat(4)55.35%
EPS beat(8)7
Avg EPS beat(8)25.71%
EPS beat(12)11
Avg EPS beat(12)24.45%
EPS beat(16)12
Avg EPS beat(16)-14.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25%
PT rev (3m)-25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.54%
EPS NY rev (1m)0%
EPS NY rev (3m)3.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.85
P/tB 1.85
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0
BVpS0.56
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -92.58%
ROE -126.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.52%
ROA(5y)-64.44%
ROE(3y)-118.44%
ROE(5y)-78.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.78
Quick Ratio 5.78
Altman-Z -44.64
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)35.21%
Cap/Depr(5y)56.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.22%
EPS Next Y53.13%
EPS Next 2Y23.86%
EPS Next 3Y12.61%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y51.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.79%
OCF growth 3YN/A
OCF growth 5YN/A

COCRYSTAL PHARMA INC / COCP FAQ

Can you provide the ChartMill fundamental rating for COCRYSTAL PHARMA INC?

ChartMill assigns a fundamental rating of 2 / 10 to COCP.


What is the valuation status for COCP stock?

ChartMill assigns a valuation rating of 0 / 10 to COCRYSTAL PHARMA INC (COCP). This can be considered as Overvalued.


How profitable is COCRYSTAL PHARMA INC (COCP) stock?

COCRYSTAL PHARMA INC (COCP) has a profitability rating of 0 / 10.


What is the earnings growth outlook for COCRYSTAL PHARMA INC?

The Earnings per Share (EPS) of COCRYSTAL PHARMA INC (COCP) is expected to grow by 53.13% in the next year.